miR‐17‐3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition
Source : https://doi.org/10.1002/ijc.33528
Kangdong Liu Corresponding Author China‐US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China Cancer Chemoprevention International Collaboration Laboratory,...
63-Year-Old Female Experiences Slow Relapse
Evelyn, now 63, was diagnosed with multiple myeloma when she was 58. She is a district manager for her company and has an erratic travel schedule. She is a current smoker.
She was considered standard risk. She had Vd induction followed by an autologous stem cell transplantation.
About three years...
-
Mark Fesler4yrElo or dara or kyprolis + rev or Pom + dex This is a situation I like elo to save bigger guns for a symptomatic relapse Could be Show More
-
Sherif Badawy4yrGiven what we know about safety and efficacy data as well as potential benefits for quality of life outcomes, adding Daratumumab and Dex would have potential clinical benefits as best Show More
Show More Comments
Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma
Source : https://pubs.acs.org/doi/abs/10.1021/acs.jproteome.1c00007
Multiple myeloma (MM) is a common hematological malignancy with poorly understood recurrence and relapse mechanisms. Notably, bortezomib resistance leading to relapse makes MM treatment significantly challenging. To clarify the drug...